[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343626-105":59,"doc-detail-343626-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immune-checkpoint-inhibitors-related-thyroid-dysfunction-influencing-factor-analysis-prediction-model-development-and-management-strategy-proposal","Immune checkpoint inhibitors-related thyroid dysfunction - influencing factor analysis - prediction model development and management strategy proposal","","Immune checkpoint inhibitors (ICIs) are widely used across cancers, and ICIs-related thyroid dysfunction (ICI-TD) has become an increasing clinical concern. This study developed an individualized management strategy to support early identification and proactive care. A three-phase workflow combined systematic review/meta-analysis of influencing factors, algorithmic model development using real-world cohort data, and evidence-based management pathway proposals, targeting improved monitoring and treatment decisions for pharmacists.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immune-checkpoint-inhibitors-related-thyroid-dysfunction-influencing-factor-analysis-prediction-model-development-and-management-strategy-proposal/343626/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immune-checkpoint-inhibitors-related-thyroid-dysfunction-influencing-factor-analysis-prediction-model-development-and-management-strategy-proposal/343626.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on ICI-TD?","Question",{"text":112,"@type":113},"To devise an individualized management strategy that enables early identification and proactive management of immune checkpoint inhibitors-related thyroid dysfunction in cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the influencing factors for ICI-TD identified?",{"text":117,"@type":113},"Through a systematic review and meta-analysis following PRISMA guidelines, with the study protocol registered in PROSPERO.",{"name":119,"@type":110,"acceptedAnswer":120},"Which prediction model performed best and how was it used?",{"text":121,"@type":113},"The LightGBM-based model showed superior performance and was used to develop a web calculator to support risk prediction.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343626,1790577350,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Immunology, Immunotherapy (2024) 74:2 [https://doi.org/10.1007/s00262-024-03816-0](https://doi.org/10.1007/s00262-024-03816-0)  \nImmune checkpoint inhibitors‑related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal  \nXinya Li1,2,3,4 · Zaiwei Song1,2,3 · Yixuan Chen1,2,3,4 · Jingjing Wu1,2,3,4 · Dan Jiang1,2,3,4 · Zhen Zhang5 · Zeyuan Wang5,6 · Rongsheng Zhao1,2,3  \nReceived: 13 April 2024 / Accepted: 22 August 2024 / Published online: 2 November 2024 © The Author(s) 2024, corrected publication 2025  \nAbstract  \nBackground With the extensive utilization of immune checkpoint inhibitors (ICIs) across various cancers, ICIs-related thyroid dysfunction (ICI-TD) has become a growing concern in clinical practice. This study aimed to devise an individualized management strategy for ICI-TD to enhance the early identification and proactive management in cancer patients.  \nMethods We designed and conducted a three-phase study. Initially, we analyzed the influencing factors through a systematic review and meta-analysis, which adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Moreover, the study protocol was registered with PROSPERO (CRD42019131133) . Subsequently, prediction models for ICI-TD were developed utilizing 11 algorithms based on the real-world cohort data from July 20, 2018 (the approval date of the first ICIs, Pembrolizumab in China), to October 31, 2022. Considering discrimination, calibration, and clinical utility, we selected the model with the best performance for web calculator development. Finally, individualized management strategies for ICI-TD were proposed by combining evidence-based analysis with practical considerations. Results The systematic review encompassed 21 observational studies involving 4,145 patients, revealing associations between ICI-TD and factors such as female gender, age, receipt of Pembrolizumab (versus other ICIs), and baseline levels of thyroidstimulating hormone, free thyroxine, and antithyroid antibodies. In the prediction model development phase, 621 participants were enrolled, with 36 patients developing ICI-TD. The model based on the LightGBM algorithm demonstrated superior performance, leading to the development of a web calculator. Based on these findings and existing guidelines, individualized monitoring and treatment pathways for pharmacists were devised.  \nConclusion This study offers comprehensive insights into managing ICI-TD, potentially enhancing tailored cancer immunotherapy management.  \nKeywords Immune checkpoint inhibitors · Immune checkpoint inhibitors-related thyroid dysfunction · ICI-TD · Risk prediction model  \nXinya Li and Zaiwei Song have contributed equally to this work.  \n* Zeyuan Wang [wangzeyuan@sentumhealth.com](wangzeyuan@sentumhealth.com)  \n* Rongsheng Zhao [zhaorongsheng@bjmu.edu.cn](zhaorongsheng@bjmu.edu.cn)  \n1 Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China  \n2 Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China  \nAbbreviations  \nAnti-CTLA-4  \nAnti-PD-L1  \nCytotoxic T lymphocyte associate protein-4  \nAnti-programmed death ligand 1  \n3 Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing 100191, China  \n4 Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China  \n5 Sentum Health, Beijing 100163, China  \n6 The University of Sydney, Sydney, Australia  \nAnti-PD-1  \nATA  \nAUC  \nBMI  \nCI  \nCTCAE  \nDCAEOS% FT3  \nFT4  \nGBDT  \nICIs  \nICI-TD  \nIQRIrAEs KNN LightGBMLYMLYM% MONO%  \nMOOSE  \nMPV  \nMI  \nNCI  \nNOS  \nNPV  \nOR  \nPPV  \nPRISMA  \nPROSPERO  \nROC  \nRR  \nSHAP  \nSMOTE  \nSVM  \nTC  \nTGTGAb TPOAb  \nTRIPOD  \nTSH  \nTT3  \nTT4  \nUA  \nAnti-programmed death receptor 1 Antithyroid antibodies  \nThe area under the receiver operating  \ncharacteristic curve Body mass index Conf","cbCaidEE3p3AKNGe","https://ap.wps.com/l/cbCaidEE3p3AKNGe","pdf",4730691,"English","# Background\n# Methods\n## Systematic review and meta-analysis\n## Prediction model development\n# Results\n# Conclusion\n# Abbreviations","[{\"question\":\"What is the main goal of this study on ICI-TD?\",\"answer\":\"To devise an individualized management strategy that enables early identification and proactive management of immune checkpoint inhibitors-related thyroid dysfunction in cancer patients.\"},{\"question\":\"How were the influencing factors for ICI-TD identified?\",\"answer\":\"Through a systematic review and meta-analysis following PRISMA guidelines, with the study protocol registered in PROSPERO.\"},{\"question\":\"Which prediction model performed best and how was it used?\",\"answer\":\"The LightGBM-based model showed superior performance and was used to develop a web calculator to support risk prediction.\"}]","Immune checkpoint inhibitors-related thyroid dysfunction - influencing factor analysis - prediction model development and management strategy proposal | PDF",1790051612,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8bacf2fb97acfd3b33664401b10aa1b.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23881f614efd90b9342b904df8247d5c.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d10d9d82a7be58f9e98bbef0cd6412e.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8278c1a85a520f09d5b82e2879360156.webp",980,1301]